Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Hepatitis C: Update Bulletin [December 2015]

Product Code:
Publication Date:
December 2015

Gain new KOL insights on the latest events happening in Hepatitis C Virus (HCV): FDA’s label directive on hepatotoxicity with AbbVie’s Viekira Pak and Technivie; Merck & Co.’s Phase II data on the combination regimen of grazoprevir (MK-5172) and MK-3682 with either elbasvir (MK-8742) or MK-8408 in subjects with chronic HCV GT3 infection; AbbVie’s two Phase II studies (SURVEYOR-1 and -2) with its pan-genotypic ABT-493 + ABT-530 combination in genotype 1-3-infected patients without cirrhosis; Gilead’s Phase II data for sofosbuvir/velpatasvir in combination with GS-9857 in more difficult-to-treat HCV patients; Gilead’s FDA filing for FDC of sofosbuvir (Sovaldi) and velpatasvir for treatment of all six HCV genotypes, based on data from four Phase III ASTRAL trials; FDA’s approval of Gilead’s Harvoni (ledipasvir/sofosbuvir) for expanded use in patients with genotype 4, 5 and 6 chronic HCV infection and in patients co-infected with HIV and Achillion’s Phase II data for odalasvir + sofosbuvir, without ribavirin, for patients with treatment-naïve (TN) GT1 chronic HCV infection.

Key Questions Answered in this Update Bulletin:

  • What KOLs say about FDA’s label directive on AbbVie’s Viekira Pak and Technivie?
  • How do KOLs view AbbVie’s Phase II SURVEYOR-1 and 2 data?
  • Will positive phase II data for Merck & Co.’s grazoprevir+MK-3682 + elbasvir/MK-8408 regimen have any bearing HCV therapies?
  • What do KOLs think of Gilead’s velpatasvir +sofosbuvir+GS9857 regimen?
  • How are the new triple combination products from Gilead, Merck and AbbVie perceived by KOLs?
  • Which pan-genotypic combination do the KOLs see as having the greatest potential?
  • Will Harvoni’s usage change in the future?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved